ChemicalBook > Product Catalog > Biochemical Engineering > Biochemical Reagents > Agonist Inhibitors > GGTI-2418
GGTI-2418
GGTI-2418 Basic information
- Product Name:
- GGTI-2418
- Synonyms:
-
- GGTI-2418
- (S)-3-benzyl-1-((4-methyl-1-trityl-1H-imidazol-5-yl)methyl)piperazin-2-one
- GGTI2418;PTX 100
- GGTI 2418 (GGTI2418
- L-Leucine, N-[[(2S)-4-[(4-methyl-1H-imidazol-5-yl)methyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]carbonyl]-
- L-Leucine, N-[[(2S)-4-[(5-methyl-1H-imidazol-4-yl)methyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]carbonyl]-
- (S)-2-((S)-2-Benzyl-4-((5-methyl-1H-imidazol-4-yl)methyl)-3-oxopiperazine-1-carboxamido)-4-methylpentanoic acid
- PTX-100 (GGTI-2418)
- CAS:
- 501010-06-6
- MF:
- C23H31N5O4
- MW:
- 441.52
- Mol File:
- 501010-06-6.mol
More
Less
GGTI-2418 Chemical Properties
- Boiling point:
- 807.5±65.0 °C(Predicted)
- Density
- 1.270±0.06 g/cm3(Predicted)
- storage temp.
- Sealed in dry,Store in freezer, under -20°C
- solubility
- DMSO:125.0(Max Conc. mg/mL);283.11(Max Conc. mM)
- form
- A crystalline solid
- pka
- 4.30±0.21(Predicted)
- color
- Light yellow to yellow
More
Less
GGTI-2418 Usage And Synthesis
Uses
GGTI 2418 is a geranylgeranyltransferase I inhibitor.
in vivo
GGTI-2418 (100 mg/kg daily or 200 mg/kg every third day; 15 days) significantly inhibits the growth of breast tumor xenografts in nude mice with MDA-MB-231 xenografts[1].
GGTI-2418 (100 mg/kg daily; 5 days) induces regression of ErbB2-driven mammary tumors in ErbB2 transgenic mice[1].
GGTI-2418 inhibits the geranylgeranylation of Rap1 and causes a dramatic decrease in S473 phosphorylation of Akt. GGTI-2418 also upregulates p27 levels in vivo[1].
| Animal Model: | Nude mice implanted with MDA-MB-231 breast cancer tumors[1] |
| Dosage: | 100 mg/kg daily or 200 mg/kg every third day |
| Administration: | Injected intraperitoneally; 15 days |
| Result: | Inhibited the growth of breast tumor xenografts. |
| Animal Model: | ErbB2 transgenic mice[1] |
| Dosage: | 100 mg/kg/day |
| Administration: | Subcutaneously; 5 days |
| Result: | Halted tumor growth and induced massive tumor regression. Tumor decreased by 76% following GGTI-2418 treatment. |
GGTI-2418Supplier
NCE Biomedical Co.,Ltd.
- Tel
- 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
AdooQ BioScience, LLC
- Tel
- +1 (866) 930-6790
- info@adooq.com
SPIRO PHARMA
- Tel
- eric_feng1954@126.com
Shanghai EFE Biological Technology Co., Ltd.
- Tel
- 021-65675885 18964387627
- info@efebio.com
ShangHai Biochempartner Co.,Ltd
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com